Picture loading failed.

Pre-Made Tilavonemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tilavonemab (formerly C2N 8E12) is a humanised recombinant anti-human tau monoclonal antibody, being developed by AbbVie and C2N Diagnostics for the treatment of various neurological disorders including Alzheimer's disease.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-572-1mg 1mg 3090
GMP-Bios-ab-572-10mg 10mg Inquiry
GMP-Bios-ab-572-100mg 100mg Inquiry
GMP-Bios-ab-572-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Tilavonemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
INN Name Tilavonemab
TargetMAPT
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAbbVie;C2N Diagnostics
Conditions Approvedna
Conditions ActiveAlzheimer's disease;Progressive supranuclear palsy
Conditions Discontinuedna
Development Techna